Results 121 to 130 of about 955 (158)

Screening telomere-related genes to predict prognosis, immunotherapy response, and drug sensitivity in esophageal cancer using a machine learning approach. [PDF]

J Cardiothorac Surg
Li S, Fang C, Tao Z, Jiang W, Zhu J, Yu X, Ma H.   +6 more
europepmc   +1 more source

Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. [PDF]

Cancer Res Commun
Yang Z, Mogre S, Jun H, He R, Ghosh Chaudhary S, Bhattarai UR, Ho Sui SJ, Matulonis UA, Lazo S, Shetty A, Cameron A, Nguyen QD, Hill SJ.   +12 more
europepmc   +1 more source

ASAH1 facilitates TNBC by DUSP5 suppression-driven activation of MAP kinase pathway and represents a therapeutic vulnerability. [PDF]

Cell Death Dis
Reddi KK, Chava S, Chabattula SC, Edwards YJK, Singh K, Gupta R.   +5 more
europepmc   +1 more source

Covalent Fragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by Nucleophilic Aromatic Substitution. [PDF]

ACS Pharmacol Transl Sci
Klett T, Stahlecker J, Jaag S, Masberg B, Knappe C, Lämmerhofer M, Coles M, Stehle T, Boeckler FM.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The p53 reactivator PRIMA-1MET synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells

Investigational New Drugs, 2023
Pancreatic cancer (PC) is one of the deadliest malignancies; p53 is mutated in approximately 75% of PC patients. Hence, the protein derived from mutant/wild-type TP53 may represent a therapeutic target. Interestingly, a p53 reactivator (PRIMA-1MET) showed promise in clinical trials of haematological malignancies; therefore, it warrants an in vitro ...
Ibtehal Mohammed, Ali Haider Alhammer, Inam Sameh Arif   +2 more
openaire   +2 more sources

PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells

Leukemia Research, 2020
TP53 gene defects represent the most unfavorable prognostic factor in chronic lymphocytic leukemia (CLL). Although recently introduced small-molecule B-cell receptor signalling inhibitors have revolutionized CLL treatment, data for ibrutinib still point to impaired prognosis for TP53-affected patients.
Zuzana, Jaskova, Sarka, Pavlova, Jitka, Malcikova, Yvona, Brychtova, Martin, Trbusek   +4 more
openaire   +2 more sources

PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis [PDF]

Oncogene, 2005
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis ...
Vladimir J N Bykov, Klas G Wiman
exaly   +3 more sources

Anti-inflammatory effects of PRIMA-1MET (mutant p53 reactivator) induced by inhibition of nuclear factor-κB on rheumatoid arthritis fibroblast-like synoviocytes

Inflammopharmacology, 2022
Fibroblast-like synoviocytes (FLSs), the main pathological cells in rheumatoid arthritis (RA), display tumor-like phenotype, including hyper-proliferation, apoptosis resistance, and aggressive phenotype. Excessive proliferation and insufficient apoptosis of RA-FLSs can lead to hyperplastic synovial pannus tissue, excess production of inflammatory ...
Mehrnoosh Adib, Mahdi Taghadosi, Mohammad Naghi Tahmasebi, Arash Sharafat Vaziri, Ahmadreza Jamshidi, Mahdi Mahmoudi, Elham Farhadi   +6 more
openaire   +2 more sources

The p53 Reactivating Drug PRIMA-1Met Induces Apoptosis Of Myeloma Cells Via ROS Production

Blood, 2013
Abstract Patients with multiple myeloma (MM) carrying a del(17)(p13) (del17p) deletion and/or TP53 mutation at diagnosis have a shortened survival whatever the treatment received. By using a large and characterized collection of human myeloma cell lines (HMCLs), we have shown that TP53mutated/deleted cell lines are more resistant to ...
Benoit Tessoulin, Géraldine Descamps, Catherine Godon, Marie C Bene, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck   +7 more
openaire   +1 more source